CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge.
Potent systemic immunity is important for recalled mucosal immune responses, but in the defense against mucosal viral infections, it usually remains low at mucosal sites. Based on our previous findings that enhanced immune responses can be achieved by immunization with an immunogen in combination with a molecular adjuvant, here we designed chemokine-antigen (Ag) fusion constructs (CCL19- or CCL28-herpes simplex virus 2 glycoprotein D [HSV-2 gD]). After intramuscular (i.m.) immunization with different DNA vaccines in a prime and boost strategy, BALB/c mice were challenged with a lethal dose of HSV-2 through the genital tract. Ag-specific immune responses and chemokine receptor-specific lymphocytes were analyzed to determine the effects of CCL19 and CCL28 in strengthening humoral and cellular immunity. Both CCL19 and CCL28 were efficient in inducing long-lasting HSV-2 gD-specific systemic immunity. Compared to CCL19, less CCL28 was required to elicit HSV-2 gD-specific serum IgA responses, Th1- and Th2-like responses of immunoglobulin (Ig) subclasses and cytokines, and CCR3+ T cell enrichment (>8.5-fold) in spleens. These findings together demonstrate that CCL28 tends to assist an immunogen to induce more potently protective immunity than CCL19. This work provides information for the application potential of a promising vaccination strategy against mucosal infections caused by HSV-2 and other sexually transmitted viruses.IMPORTANCE An effective HSV-2 vaccine should induce antigen (Ag)-specific immune responses against viral mucosal infection. This study reveals that chemokine CCL19 or CCL28 enhanced HSV-2 glycoprotein D ectodomain (gD-306aa)-induced immune responses against vaginal virus challenge. In addition to eliciting robust humoral immune responses, the chemokine-Ag fusion construct also induced Th1- and Th2-like immune responses characterized by the secretion of multiple Ig subclasses and cytokines that were able to be recalled after HSV-2 challenge, while CCL28 appeared to be more effective than CCL19 in promoting gD-elicited immune responses as well as the migration of T cells to secondary lymph tissues. Of importance, both CCL19 and CCL28 significantly facilitated gD to induce protective mucosal immune responses in the genital tract. The above-described findings together highlight the potential of CCL19 or CCL28 in combination with gD as a vaccination strategy to control HSV-2 infection.
['Yan|Yan|Y|', 'Hu|Kai|K|', 'Fu|Ming|M|', 'Deng|Xu|X|', 'Luo|Sukun|S|', 'Tong|Lina|L|', 'Guan|Xinmeng|X|', 'He|Siyi|S|', 'Li|Chang|C|', 'Jin|Wei|W|', 'Du|Tao|T|', 'Zheng|Zifeng|Z|', 'Zhang|Mudan|M|', 'Liu|Yalan|Y|', 'Hu|Qinxue|Q|0000-0002-4594-9215']
D000276:Adjuvants, Immunologic D000818:Animals D000914:Antibodies, Viral D054415:Chemokine CCL19 D019742:Chemokines, CC D005260:Female D022301:Herpes Simplex Virus Vaccines D018258:Herpesvirus 2, Human D018928:Immunity, Mucosal D007156:Immunologic Memory D051379:Mice D008807:Mice, Inbred BALB C D014611:Vaccination D014621:Vagina D014759:Viral Envelope Proteins
CCL19 CCL28 glycoprotein D mucosal immunity HSV-2